Anemia Clinical Trial
Official title:
Cardiopulmonary Exercise Testing Before and After Intravenous Iron: a Prospective Clinical Study
Red blood cells contain a chemical called haemoglobin which carries oxygen from the lungs
around the body. When the amount of haemoglobin is reduced, a patient is 'anaemic'. Anaemia
can have many causes, but affects about a third of patients having major surgery in hospital.
After their operation these anaemic patients are more likely to suffer serious complications.
This may be because the body needs extra oxygen - and so enough haemoglobin - to heal and
recover successfully from the trauma of surgery.
For a similar reason, patients' overall fitness before surgery is very important. Less fit
patients are much more likely to get complications after surgery. To help us assess the risk
of complications, the investigators measure patients' fitness before surgery using a cycling
exercise test. The investigators monitor a number of things that show us how well the heart,
the lungs and the muscles respond when they are under stress. People who are very anaemic
tend to perform less well on this cycling test.
Anaemia is often due to a lack of iron, which helps make haemoglobin. Usually people get iron
from foods such as red meat and spinach. Some conditions mean that patients lose iron, such
as a tumour bleeding. Other illnesses make it difficult for the body to absorb iron from the
gut in the first place. Both lead to a state of low iron in the body and eventually this
leads to anaemia. One way to treat anaemia quickly before surgery is to give iron into the
bloodstream (intra-venous). It is thought that this might reduce the risk of complications
after surgery, but it is not known whether this is because it improves overall fitness, or
for other reasons.
The investigators plan to carry out a study called CAPOEIRA-I (CArdio PulmOnary Exercise
testing and IntRAvenous Iron) to find out whether giving patients intravenous iron improves
their fitness. The investigators will measure this by doing a cycle exercise test before and
then at least 10 days after the iron is given. The investigators will also measure how much
the total amount of haemoglobin chnages with iron treatment. Intravenous iron is already
routinely used for these patients, so the only additional activity for the study is the extra
exercise test, some extra blood tests and the measurement of haemoglobin after the iron has
taken effect.
Anaemia is common in the elective surgical population, a prevalence of around 30% being
consistently reported in large cohorts.
Cardiopulmonary exercise testing (CPET), which provides an objective assessment of aerobic
fitness by measuring oxygen consumption (O2) and carbon dioxide production is widely
considered the gold standard assessment of functional capacity as it dynamically tests the
pulmonary, cardiovascular and musculoskeletal system and their interplay in a single test.
CPET parameters are affected by a number of patient factors including effort, ability to turn
the pedals on an exercise bike, pulmonary function, and crucially oxygen delivery to the
respiring tissues, which is dependent on blood oxygen content and flow to the tissues via
cardiac output.
The oxygen carrying capacity of arterial blood is largely influenced by the haemoglobin
content (or total haemoglobin mass (tHb-mass)). tHb-mass affects CPET performance to a
greater degree than haemoglobin concentration ([Hb]). [Hb] is dependent on plasma volume (PV)
and shows a greater fluctuation day to day than tHb-mass.
Studies in athletes show the detrimental affect of blood volume loss (i.e. deliberate
venesection) and haemoglobin content loss on CPET performance. The corollary of this is
illegal blood manipulation, which improves CPET performance. The same is seen post altitude
training camps with increased tHb-mass leading to improved maximal exercise performance.
Aerobic capacity is defined as the maximum amount of oxygen that can be consumed by the body
per unit time and is the gold standard measure of physical fitness. VO2max is classically
defined as 'a plateau in oxygen uptake attained during maximal exercise despite further
increases in exercise workload, thereby defining the limits of the cardiorespiratory system'.
However, many individuals do not reach a plateau in oxygen uptake despite maximum exertion,
and the term VO2peak is used instead. This is the highest measured oxygen consumption during
exercise and is typically averaged over a 30 second period. O2 at anaerobic threshold (VO2AT)
is defined as: 'the highest sustained intensity of exercise for which the measurement of
oxygen uptake can account for the entire energy requirement.' An alternative definition is
'the exercise intensity at which lactate starts to accumulate in the blood stream above
rest'. These oxygen uptake variables are in part dependent on the oxygen carrying capacity of
the blood, which is in turn dependent on blood haemoglobin levels.
Major surgery places an increased metabolic demand on the body. Perhaps for this reason, both
lower preoperative VO2peak and VO2AT values are associated with increased morbidity and
mortality after major surgery. Much of the literature in this area is derived from studies
reporting CPET variables. Given that the oxygen uptake variables VO2peak and VO2AT are
positively correlated with tHb-mass, it may be that some of the physical fitness-outcome
relationship is mediated through haemoglobin-related effects rather than cardiorespiratory
function, providing a mechanistic basis to poor CPET performance in many patients with
anaemia.
Few studies have examined the impact of blood manipulation - either transfusion or iron
therapy - on CPET variables in patients. A study by Wright et al examined 20 patients with
chronic anaemia due to 'stable haematological conditions' requiring blood transfusions. A
CPET was performed before the blood transfusion and repeated 2-6 days after the transfusion
of 1-4 units of blood (median 3). A mean rise in [Hb] from 8.3-11.2 g dl-1 was associated
with a mean (SD) rise in O2AT from 10.4 (2.4) to 11.6 (2.5) mlkg-1min -1, (p= 0.018). (10).
When corrected for the change in Hb concentration, the anaerobic threshold increased by a
mean (SD) of 0.39 (0.74) ml kg-1 min-1 per g dl-1 Hb.
The results were consistent with a study in patients with beta thalassaemia major that
compared exercise performance before, and 2 hours after haemotransfusion. Exercise duration
increased from 7.3 (+/- 2.8) to 10.3 (+/- 2.3) minutes (p<0.05), and O2 peak increased from
28.5 (+/- 5.0) to 36.2 (+/- 7.1) ml kg-1min-1; (p<0.05).
Measuring haemoglobin concentration vs. total haemoglobin mass
Traditionally, the concentration of circulating haemoglobin [Hb] has been used as a clinical
measure of the blood's oxygen carrying capacity. However, a low [Hb] may be due to a reduced
amount of haemoglobin (absolute mass of circulating haemoglobin; tHb-mass) or an increased
volume of dilution (plasma volume). Thus, [Hb] may be stable and tHb-mass low in the context
of acute bleeding, [Hb] normal or elevated but tHb-mass low in the context of dehydration, or
[Hb] low but tHb-mass normal or high in the context of excess plasma volume (fluid).
Therefore, the use of [Hb] to define blood oxygen carrying capacity may be misleading under
some circumstances.
tHb-mass represents the absolute mass of circulating haemoglobin in the body, the measured
[Hb] being dependent upon tHb-mass and blood volume (BV) (sum of plasma volume (PV) and total
red cell volume]). The proportion of oxygen carried in solution in plasma is trivial (0.3 ml
per 100 ml of plasma) under normal physiological conditions, whereas each gram of Hb binds up
to 1.39 mL of oxygen. Thus, tHb-mass is the principal determinant of total blood O2-carrying
capacity and may provide additional information regarding the clinical status of patients
than that provided by [Hb] alone.
Alternatively, a recently developed blood test capable of estimating absolute vascular
volumes may be applied as a direct test to correct for any plasma volume fluctuations
influencing a [Hb] value. As the model requires only a simple blood sample it may be a
suitable alternative to estimate vascular volumes (and tHb-mass) if the patient is unable to
perform the oCOR technique.
Classification of anaemia
The terminology around the classification of anaemia can be complex. There is no single
laboratory parameter comprehensively reflecting the overall iron status of an individual. The
POAS pathway used at UHS simplifies this (Appendix 1). In the perioperative period there are
a number of possible causes of iron-related anaemia:
- Iron deficiency: Ferritin <30 g,l-1
- Iron deficiency and functional iron deficiency (FID) (ferritin 30-100g.l-1 with TSAT
<20% and a CRP >5.
- Iron restriction/deplete Ferritin 30-100 with TSAT >20% or CRP raised/normal.
- If Ferritin is >100g,l-1 cause of anaemia could be non iron deficient anaemia or FID
- Functional iron deficiency: insufficient iron incorporation into erythroid precursors
despite apparently adequate body iron stores. Recognised by the presence of stainable
iron in the bone marrow, with a normal serum ferritin value,
- Anaemia of chronic inflammation: functional iron deficiency caused by chronic
inflammation.
- A blood film is useful to detect iron deficiency alongside FID to determine which
patients may benefit from iron therapy.
The investigators have defined how anaemia is classified and who would be eligible for
intravenous iron therapy based on international consensus and local hospital guidelines.
Patients who do not fall into the clear groups of iron deficiency, iron repletion or
functional iron deficiency as per the POAS guidance are not suitable for intravenous iron and
will not be eligible for this study.
Research statement
Preoperative anaemia is common, and is associated with poorer outcomes after major surgery.
Impaired physical performance, as assessed by CPET, is likewise associated with impaired
outcomes, and may be partly due to pre-operative anaemia.
The investigators wish to test the feasibility of performing a CPET test then administering
intravenous iron and repeating a CPET prior to surgery in patients being considered for
elective surgery. The investigators want to find out if treating anaemic patients who are
suitable for intravenous iron therapy affects their CPET variables. This will help to inform
further work to see if intravenous iron therapy combined with CPET adjusted risk
stratification improves morbidity and/or mortality for anaemic patients undergoing major
elective surgery.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Completed |
NCT02948283 -
Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Completed |
NCT03341338 -
Genes-in-Action - Hepcidin Regulation of Iron Supplementation
|
||
Completed |
NCT00060398 -
Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer
|
Phase 3 | |
Recruiting |
NCT05384691 -
Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions
|
Phase 2 | |
Not yet recruiting |
NCT06309641 -
Methemoglobinemia Following Intravenous Iron Treatment
|
||
Completed |
NCT02912533 -
A Long-term Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
|
Phase 3 | |
Completed |
NCT02912494 -
A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
|
Phase 3 | |
Completed |
NCT03822884 -
Pharmacokinetic/Pharmacodynamic Study of 3 Subcutaneous Single Dose Epoetin Alfa Formulations in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT02930850 -
Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation
|
N/A | |
Completed |
NCT02888171 -
Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency
|
N/A | |
Completed |
NCT02603250 -
Evaluation of Hemoglobin Measurement Tools for Child Anemia Screening in Rwanda
|
N/A | |
Completed |
NCT02384122 -
Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias
|
Phase 3 | |
Completed |
NCT02176759 -
Iron Absorption From Rice Fortified With Ferric Pyrophosphate
|
N/A | |
Withdrawn |
NCT01934842 -
A Study to Compare Analyte Levels in Blood Collected Using an Investigational Collection Device With a Commercial Predicate
|
N/A | |
Completed |
NCT02310113 -
Transfusion and Skeletal Muscle Tissue Oxygenation
|
N/A | |
Completed |
NCT01922479 -
Pilot Study of Ferric Carboxymaltose to Treat Iron Deficiency in Asians With Heart Failure
|
Phase 4 | |
Completed |
NCT01693029 -
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
|
Phase 3 | |
Completed |
NCT01458028 -
Age and Gender Effects on the Pharmacokinetics of BAY85-3934
|
Phase 1 | |
Terminated |
NCT01535781 -
Study of the Effect of Tranexamic Acid Administered to Patients With Hip Fractures. Can Blood Loss be Reduced?
|
N/A |